Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDUARDO DUSTY LUNA

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1073959326
CMS profile
650321
Location
EDINBURG, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$24,743.20

146 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDUARDO DUSTY LUNA

NPI 1073959326 · CMS profile ID 650321

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

EDINBURG, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073959326?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDUARDO DUSTY LUNA, NPI 1073959326, CMS profile ID 650321. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073959326?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). EDUARDO DUSTY LUNA, NPI 1073959326, CMS profile ID 650321. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073959326?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
EDUARDO DUSTY LUNA, NPI 1073959326, CMS profile ID 650321, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–146 of 146 matching records. This page contains 46 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1073959326?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

146 matching records · $24,743.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 146 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–146 of 146.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $107.5504/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679361057 CMS
Janssen Pharmaceuticals, Inc $17.8604/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658944257 CMS
Amgen Inc. $24.1704/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662318371 CMS
Merck Sharp & Dohme Corporation $12.1504/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695425591 CMS
Abbott Laboratories $11.6704/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679361143 CMS
Abbott Laboratories $3.2904/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679364143 CMS
Abbott Laboratories $5.8704/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679364631 CMS
Abbott Laboratories $6.3604/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679364799 CMS
Abbott Laboratories $1,250.0004/09/2019 Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679361477 CMS
Abbott Laboratories $135.2504/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679361785 CMS
Abbott Laboratories $525.0004/09/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679364675 CMS
Merck Sharp & Dohme Corporation $5.5204/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695396471 CMS
Alexion Pharmaceuticals, Inc. $32.2804/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695485039 CMS
Merck Sharp & Dohme Corporation $5.6303/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695379467 CMS
Radius Health, Inc. $20.0503/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683950679 CMS
Radius Health, Inc. $24.4703/26/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683950685 CMS
Abbott Laboratories $218.7503/25/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679363619 CMS
Abbott Laboratories $900.0003/25/2019 Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679365231 CMS
Abbott Laboratories $0.5003/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679360923 CMS
Abbott Laboratories $5.6503/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679364619 CMS
Abbott Laboratories $8.5203/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679365067 CMS
Abbott Laboratories $86.7603/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679365131 CMS
Abbott Laboratories $117.5603/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679361241 CMS
Lilly USA, LLC $13.4403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657803509 CMS
Abbott Laboratories $5.1903/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679364611 CMS
Abbott Laboratories $5.8403/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679364629 CMS
Merck Sharp & Dohme Corporation $12.5503/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695323713 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.7402/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700080539 CMS
Abbott Laboratories $111.7202/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679361195 CMS
Abbott Laboratories $111.7202/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679361197 CMS
Abbott Laboratories $161.6302/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679362763 CMS
Abbott Laboratories $161.6302/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679362765 CMS
Abbott Laboratories $294.7302/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679364131 CMS
Abbott Laboratories $690.6402/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679364901 CMS
Abbott Laboratories $7.9902/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696944413 CMS
Merck Sharp & Dohme Corporation $6.8102/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695263131 CMS
SANOFI-AVENTIS U.S. LLC $12.2502/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694274269 CMS
Abbott Laboratories $90.9902/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679365219 CMS
Lilly USA, LLC $13.4602/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657792915 CMS
SANOFI-AVENTIS U.S. LLC $18.9902/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693924097 CMS
Merck Sharp & Dohme Corporation $7.4302/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695226469 CMS
Abbott Laboratories $9.3801/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679365195 CMS
SANOFI-AVENTIS U.S. LLC $21.3401/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693900001 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.5901/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700040553 CMS
Merck Sharp & Dohme Corporation $16.1401/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695218751 CMS
Abbott Laboratories $30.8301/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679364173 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $24,743.20 146
PY2020 $58,996.63 131
PY2021 $119,322.84 250
PY2022 $215,937.31 405
PY2023 $270,032.76 492
PY2024 $297,010.60 556
PY2025 $299,262.69 546

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,123,757.93 45
PY2024 Recipient $42,164.92 13
PY2024 Principal investigator $2,429,401.71 40
PY2023 Recipient $22,795.95 5
PY2023 Principal investigator $781,915.42 13
PY2022 Recipient $15,816.00 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $7,968.00 12/31/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202534293
Principal investigator 1 Eli Lilly and Company $915.38 12/17/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187891202
Principal investigator 1 Eli Lilly and Company $934.02 12/17/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187891764
Principal investigator 1 ABBVIE INC. $4,820.64 12/05/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529442
Principal investigator 1 Amgen Inc. $306.08 11/10/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH
A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease No dispute reported 06/30/2026 1246649363
Principal investigator 1 ABBVIE INC. $24,228.60 11/05/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202521733
Principal investigator 1 ABBVIE INC. $4,338.64 10/09/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513909
Principal investigator 1 ABBVIE INC. $8,672.00 10/09/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513911
Principal investigator 1 ABBVIE INC. $12,328.80 10/09/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202513913
Principal investigator 1 ABBVIE INC. $21,984.60 09/04/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508864
Principal investigator 1 ABBVIE INC. $19,833.00 08/06/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202502270
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,823.00 07/28/2025 Non-covered Recipient Entity
COMPREHENSIVE CENTER
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190312719
Principal investigator 1 ABBVIE INC. $9,698.04 07/02/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494749
Principal investigator 1 ABBVIE INC. $39,732.00 06/03/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202489725
Principal investigator 1 Eli Lilly and Company $143,697.00 05/12/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND LONG-TERM SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-2) No dispute reported 06/30/2026 1187892142
Principal investigator 1 ABBVIE INC. $13,713.48 05/07/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483771
Principal investigator 1 Eli Lilly and Company $155,888.00 05/06/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL No dispute reported 06/30/2026 1187893342
Principal investigator 1 ABBVIE INC. $4,308.48 04/03/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202471169
Principal investigator 1 ABBVIE INC. $10,449.12 03/07/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459620
Principal investigator 1 Eli Lilly and Company $15,100.00 02/11/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187892138
Principal investigator 1 ABBVIE INC. $28,311.36 02/06/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202449447
Principal investigator 1 Eli Lilly and Company $81,790.00 02/03/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) No dispute reported 06/30/2026 1187891194
Principal investigator 1 Eli Lilly and Company $610,508.00 02/03/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187892124
Principal investigator 1 Eli Lilly and Company $1,552.56 01/31/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187892140
Principal investigator 1 Eli Lilly and Company $3,364.14 01/31/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187893488
Principal investigator 1 Eli Lilly and Company $3,812.36 01/31/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187893490
Principal investigator 1 Eli Lilly and Company $10,300.59 01/31/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187893492
Principal investigator 1 Eli Lilly and Company $364,700.00 01/28/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) No dispute reported 06/30/2026 1187892808
Principal investigator 1 Eli Lilly and Company $11,658.97 01/24/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR THE TREATMENT OF OBESITY AND WEIGHT-RELATED COMORBIDITIES IN ADOLESCENTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED TRIAL (SURMOUNT-ADOLESCENTS-2) No dispute reported 06/30/2026 1187890552
Principal investigator 1 Eli Lilly and Company $3,235.35 01/24/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187893494
Principal investigator 1 Eli Lilly and Company $102,825.00 01/21/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187890554
Principal investigator 1 Eli Lilly and Company $119,034.00 01/21/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187890556
Principal investigator 1 Eli Lilly and Company $113,072.00 01/21/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187890786
Principal investigator 1 Eli Lilly and Company $114,332.00 01/21/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187891196
Principal investigator 1 Eli Lilly and Company $2,557.06 01/21/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187892122
Principal investigator 1 Eli Lilly and Company $2,144.18 01/20/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187890558
Principal investigator 1 Eli Lilly and Company $13,833.32 01/09/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187891762
Principal investigator 1 Eli Lilly and Company $3,372.30 01/09/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187893486
Principal investigator 1 Eli Lilly and Company $299,948.00 01/07/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187890788
Principal investigator 1 Eli Lilly and Company $49,694.00 01/07/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187891198
Principal investigator 1 Eli Lilly and Company $42,958.00 01/07/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) No dispute reported 06/30/2026 1187891200
Principal investigator 1 Eli Lilly and Company $617,110.00 01/07/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187893344
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $3,530.19 01/03/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) No dispute reported 06/30/2026 1187891766
Principal investigator 1 Eli Lilly and Company $4,523.20 01/02/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) No dispute reported 06/30/2026 1187891760
Principal investigator 1 Eli Lilly and Company $8,852.47 01/02/2025 Non-covered Recipient Entity
TEXAS VALLEY CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187892806